文献速递产科母胎医学

阿司匹林用于循证子痫前期预防试验:依从性对阿司匹林预防早产子痫前期有益效果的影响

Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
PubMed 文献 · Am J Obstet Gynecol · 2017-09-06

本分析基于阿司匹林用于循证子痫前期预防试验的二次分析,评估依从性对阿司匹林预防早产子痫前期效果的影响。依从性≥90%者阿司匹林组早产子痫前期发生率为0.9%(5/555),安慰剂组为3.7%(22/588),OR 0.24(95%CI 0.09-0.65);依从性<90%者阿司匹林组为3.3%(8/243),安慰剂组为5.6%(13/234),OR 0.59(95%CI 0.23-1.53)。结论认为阿司匹林预防早产子痫前期的有益效果似乎取决于依从性。

要点

  • 依从性≥90%者阿司匹林组早产子痫前期发生率0.9%(5/555),安慰剂组3.7%(22/588),OR 0.24(95%CI 0.09-0.65)。
  • 依从性<90%者阿司匹林组早产子痫前期发生率3.3%(8/243),安慰剂组5.6%(13/234),OR 0.59(95%CI 0.23-1.53)。
  • 依从性与子痫前期家族史正相关,与吸烟、母亲年龄<25岁、非洲-加勒比和南亚种族起源及既往子痫前期病史负相关。

核心结论

  • 阿司匹林预防早产子痫前期的有益效果似乎取决于依从性。

研究设计与样本

  • 本分析为阿司匹林用于循证子痫前期预防试验的二次分析,该试验为多中心、双盲、安慰剂对照研究,纳入单胎妊娠孕妇。
  • 筛查于妊娠11-13周进行,采用结合母体因素和生物标志物(平均动脉压、子宫动脉搏动指数、母体血清妊娠相关血浆蛋白A和胎盘生长因子)的算法。
  • 估计早产子痫前期风险>1/100者被邀请参与,从11-14周至36周妊娠接受阿司匹林(150 mg/d)或安慰剂。

主要发现

  • 依从性≥90%者,阿司匹林组早产子痫前期发生率为0.9%(5/555),安慰剂组为3.7%(22/588),阿司匹林组OR 0.24(95%CI 0.09-0.65)。
  • 依从性<90%者,阿司匹林组早产子痫前期发生率为3.3%(8/243),安慰剂组为5.6%(13/234),阿司匹林组OR 0.59(95%CI 0.23-1.53)。
  • 依从性与子痫前期家族史正相关,与吸烟、母亲年龄<25岁、非洲-加勒比和南亚种族起源及既往子痫前期病史负相关。

关键数值与推荐

  • 依从性≥90%时,阿司匹林组早产子痫前期OR 0.24(95%CI 0.09-0.65)。
  • 依从性<90%时,阿司匹林组早产子痫前期OR 0.59(95%CI 0.23-1.53)。
  • 依从性阈值90%基于治疗效果的探索性分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies. Screening was carried out at 11-13 weeks' gestation with an algorithm that combines maternal factors and biomarkers (mean arterial pressure, uterine artery pulsatility index, and maternal serum pregnancy-associated plasma protein A and placental growth factor). Those with an estimated risk for preterm preeclampsia of >1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks' gestation. Preterm preeclampsia with delivery at <37 weeks' gestation, which was the primary outcome, occurred in 1.6% (13/798) participants in the aspirin group, as compared with 4.3% (35/822) in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.74). OBJECTIVE: We sought to examine the influence of compliance on the beneficial effect of aspirin in prevention of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial. STUDY DESIGN: This was a secondary analysis of data from the trial. The proportion of prescribed tablets taken was used as an overall measure of compliance. Logistic regression analysis was used to estimate the effect of aspirin on the incidence of preterm preeclampsia according to compliance of <90% and ≥90%, after adjustment for the estimated risk of preterm preeclampsia at screening and the participating center. The choice of cut-off of 90% was based on an exploratory analysis of the treatment effect. Logistic regression analysis was used to investigate predictors of compliance ≥90% among maternal characteristics and medical history. RESULTS: Preterm preeclampsia occurred in 5/555 (0.9%) participants in the aspirin group with compliance ≥90%, in 8/243 (3.3%) of participants in the aspirin group with compliance <90%, in 22/588 (3.7%) of participants in the placebo group with compliance ≥90%, and in 13/234 (5.6%) of participants in the placebo group with compliance <90%. The odds ratio in the aspirin group for preterm preeclampsia was 0.24 (95% confidence interval, 0.09-0.65) for compliance ≥90% and 0.59 (95% confidence interval, 0.23-1.53) for compliance <90%. Compliance was positively associated with family history of preeclampsia and negatively associated with smoking, maternal age <25 years, Afro-Caribbean and South Asian racial origin, and history of preeclampsia in a previous pregnancy. CONCLUSION: The beneficial effect of aspirin in the prevention of preterm preeclampsia appears to depend on compliance.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wright D, Poon LC, Rolnik DL, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017. PMID: 28888591. doi:10.1016/j.ajog.2017.08.110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。